

## Review Article

# Targeting HMGB1 in Acute Pancreatitis

Daolin Tang\*, Michael Lotze, Herbert J Zeh and Rui Kang\*

Department of Surgery, University of Pittsburgh Cancer Institute, USA

\*Corresponding author: Rui Kang and Daolin Tang, Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA, Tel: 412-6231211; Fax: 412-6231212; Email: kangr@upmc.edu, tangd2@upmc.edu

Received: August 08, 2014; Accepted: December 03, 2014; Published: December 03, 2014

## Abstract

High Mobility Group Box 1 (HMGB1) is normally a non-histone nuclear protein that acts as a DNA chaperone with DNA binding and bending activity. Besides its intracellular function, extracellular HMGB1 is an inducer, sensor, mediator, and effect or in the innate immune response to infection and sterile inflammation. We recently demonstrated that HMGB1 is an important regulator of the links between local tissue injuries and the systemic inflammatory response in acute pancreatitis. Deficiency of endogenous pancreatic HMGB1 in experimental acute pancreatitis leads to oxidative stress-mediated nuclear catastrophe and nucleosome (including histone and DNA) release, which then recruits and activates macrophages, with subsequent HMGB1 release locally and into the circulation. Neutralizing extracellular histone and HMGB1 protects against acute pancreatitis in conditional pancreas-specific HMGB1 knockout mice. Thus, HMGB1 has a dual role in the pathogenesis of pancreatitis, shedding light on the role of the innate immune response in infection and tissue damage.

**Keywords:** HMGB1; DAMPs; Acute Pancreatitis; sRAGE

## Introduction

### Sterile inflammatory response in acute pancreatitis

Acute pancreatitis is an inflammatory condition of the pancreas often caused by gallstones and heavy alcohol abuse. Acute pancreatitis exhibits a broad clinical spectrum of findings varying from mild and self-limited to severe, catastrophic illness. Its most severe form, necrotizing pancreatitis, presents local pancreatic injury, multiple organ failure, a systemic inflammatory response, and high mortality rates [1]. Under normal conditions, digestive enzymes or proteases (e.g., trypsin, elastase, and lipase) are stored in zymogen granules in an inactive form. In pancreatitis, these proteases are activated within the pancreatic acinar cells and lead to organelle injury and auto digestion of the pancreas [2]. Apart from local tissue injury, Systemic Inflammatory Response Syndrome (SIRS) is the major pathobiological process responsible for the morbidity and mortality of severe acute pancreatitis. Acute pancreatitis is usually a sterile inflammatory disorder involving a complex cascade of interacting immune cells and inflammatory mediators. Several inflammatory mediators are initially released by pancreatic acinar cells and result in the recruitment and activation of neutrophils, monocytes, and macrophages [3-6], which lead to further inflammatory mediator release, acinar cell injury, and SIRS [7]. Damage-Associated Molecular Pattern molecules (DAMPs) are endogenous molecules released by dead, dying, and injured cells that mediate the response to inflammation and immunity through various DAMP receptors such as Toll-Like Receptors (TLRs) and the Receptor for Advanced Glycation End product (RAGE) [8-10]. Increasing evidence indicates that DAMPs (including nuclear and mitochondrial DAMPs) promote the progression from local pancreatic damage to SIRS in acute pancreatitis; play a central role in the pathogenesis of multisystem organ failure; and could constitute a promising molecular target for therapeutic approaches to acute pancreatitis [11]. Our recent study implicates that High Mobility Group Box 1 (HMGB1), a classical nuclear DAMP, plays a dual role in acute pancreatitis (Figure 1). In this mini-review, we will introduce

the basic function of HMGB1 and focus on how HMGB1 regulates the development of acute pancreatitis.

### The double life of HMGB1

HMGB1 is a member of a family of highly-conserved proteins containing HMG box domains among species. It has two homologous HMG boxes (termed box A and box B) and one short acidic tail. HMGB1 has multiple functions in health and disease, depending on its location and modification [12]. In the nucleus, HMGB1 is a non-histone chromosome protein that binds to DNA, facilitating numerous nuclear events such as maintenance of genome stability, nucleosome sliding, gene transcription, DNA repair, and V(D)J recombination [13-16]. In the cytosol, HMGB1 is a positive autophagy regulator that binds to Beclin-1 protein, contributing to autophagosome initiation [17-19]. In the cell membrane, HMGB1 facilitates cell migration and neurite outgrowth in a RAGE-dependent manner. In addition to intracellular function, HMGB1 can also act as a DAMP when passively released from injured cells or actively secreted from immune cells [8,20-22]. Once released, HMGB1 binds to a number of receptors (e.g., TLR2, TLR4, TLR9, and RAGE) and mediates the recruitment of inflammatory cells and the release of proinflammatory cytokines (e.g., tumor necrosis factor- $\alpha$  and interleukin-6) [23]. Apart from a direct receptor interaction, HMGB1 can be taken up by cancer and immune cells, triggering energy metabolism and inflammasome activation, respectively [24,25]. Special attention has been paid in recent years to the regulation of extracellular HMGB1 activity by its partner, receptor, redox status, and cleavage [12]. For example, extracellular HMGB1 can exist in a hetero complex with other molecules, such as interleukin-1, C-X-C motif chemokine 12, DNA, nucleosome, or lipopolysaccharide, that produce synergistic effects in many cell processes [26]. Reduced HMGB1 triggers autophagy and has immune activity, whereas oxidized HMGB1 induces apoptosis and loses immune activity [27]. Overall, serum HMGB1 levels are elevated in patients with many diseases, especially inflammation-associated diseases, and may serve as a valuable biomarker [12]. More

studies are needed to clearly elucidate the role of HMGB1 in disease.

### Extracellular HMGB1 mediates acute pancreatitis

Several studies have confirmed that serum levels of HMGB1 are significantly elevated and correlate with the severity of patients with acute pancreatitis [28,29]. For instance, Yasuda *et al.* observed that serum HMGB1 levels in patients with severe acute pancreatitis ( $5.4 \pm 1.3$  ng/mL) on admission (within 72 hours after onset) was higher than those in healthy subjects ( $1.7 \pm 0.3$  ng/mL) [28]. Kocsis *et al.* reported that circulating HMGB1 levels were higher in patients with severe acute pancreatitis ( $13.33 \pm 2.11$  ng/ml) than matched healthy controls ( $0.161 \pm 0.03$  ng/ml) or patients with mild pancreatitis ( $2.64 \pm 0.185$  ng/ml) [29]. Soluble RAGE (sRAGE), which lacks the transmembrane and the signaling domain, has the ability to compete with HMGB1 to bind membrane-bound RAGE. In patients with acute pancreatitis, the serum levels of sRAGE inversely correlate with serum levels of HMGB1 [29]. In contrast, serum DNA level may positively correlate with HMGB1 level in patients with acute pancreatitis [29]. Additionally, a significant linear correlation exists between circulating HMGB1 levels and disease score, as well as other serum acute-phase proteins [28]. Interestingly, one study reports that sRAGE, but not HMGB1, is increased in patients with acute pancreatitis [30]. Thus, these findings suggest a complex relationship between HMGB1 and sRAGE in acute pancreatitis.

In several experimental animal models of acute pancreatitis, the level of HMGB1 in the serum and injured organs is significantly increased [31-33]. Inhibition of HMGB1 activity with specific neutralizing antibody from Shino-Test Corporation (Sagamihara, Japan) protects against severe acute pancreatitis and limits lung, liver, and renal dysfunction as well as bacterial translocation to the pancreas [34]. Ethyl pyruvate, a key intermediate of glucose metabolism, has been shown to protect against lethal sepsis partly by inhibition of HMGB1 release [35]. Moreover, early blockade or delayed therapeutic delivery with ethyl pyruvate reduces serum HMGB1 level, ameliorates extra pancreatic organ (e.g., lung, liver, and intestine) injury, and protects rats against established severe acute pancreatitis [36-40]. Danaparoid sodium is a low molecular weight heparinoid with anticoagulant and anti-inflammatory effects. The anti-inflammatory activity of danaparoid sodium against cerulein injection caused acute pancreatitis in rats, which is partly mediated through inhibition of HMGB1 release [41]. In addition, HMGB1-A box [42], pyrrolidine dithiocarbamate [43], antithrombin III [44], honokiol [45], cisplatin [46], and scolopendra sub spinipes mutilans [47] inhibit HMGB1 translocation, release, or activity, which therefore reduces pancreatic injury in severe acute pancreatitis. Thus, extracellular HMGB1 mediates the inflammatory response and organ dysfunction and is likely an effective therapeutic target of acute pancreatitis.


### Intracellular HMGB1 protects against acute pancreatitis

To investigate the role of intracellular HMGB1 in the response to local tissue injury and subsequent systemic inflammatory responses, we recently created mice with pancreas-specific disruption in *Hmgb1* (Pdx1-Cre; HMGB1<sup>fllox/fllox</sup>, termed CH mice) through using a Cre/LoxP system [48]. As a control, HMGB1<sup>fllox/fllox</sup> mice were termed F/F mice. Both CH and F/F mice are born alive without developmental deficiencies. However, in contrast to F/F mice, the CH mice had more severe experimental acute pancreatitis and very high mortality

rates in L-arginine- and cerulein-induced acute pancreatitis [48]. Hematoxylin and eosin stains showed exaggerated death of acinar cells, infiltration of leukocytes, and edema of interstitial issue in the CH mice compared to F/F mice during acute pancreatitis [48]. Serum amylase, the most widely-used marker in the assessment of acute pancreatitis severity, was elevated in CH mice during acute pancreatitis [48]. Moreover, the levels of pancreatic myeloperoxidase (a marker for pancreatic neutrophil recruitment) and serum lactate dehydrogenase (a marker for pancreatic necrosis) were significantly increased in the CH mice compared to F/F mice during acute pancreatitis [48]. The most important step in initiating acute pancreatitis is the activation of intrapancreatic trypsinogen to trypsin [49]. As expected, experimental acute pancreatitis-induced intrapancreatic trypsin activity was also increased in CH mice compared to F/F mice [48]. Binding of HMGB1 to histone and DNA sustains chromosome structure and function. We subsequently observed that loss of HMGB1 in pancreatic acinar cells increased the levels of  $\gamma$ -H2AX (a marker for DNA damage), cleaved-poly ADP ribose polymerase, and cleaved-caspase3 (markers for apoptosis); release of histones/DNA; and activation of inflammatory signaling pathways (e.g., NF- $\kappa$ B and mitogen-activated protein kinases) [48]. Besides HMGB1, histones and DNA are proinflammatory nuclear DAMPs and their release is regulated by oxidative stress. Blocking histone/DNA release has been demonstrated to protect against several inflammation-associated diseases [50]. These findings therefore indicate that intracellular HMGB1 protects against acute pancreatitis through limiting histone and DNA release.

### Neutralization of extracellular histone and HMGB1 confers protection against acute pancreatitis in HMGB1 conditional knockout mice

Surprisingly, we observed higher serum HMGB1 in CH mice following experimental acute pancreatitis, suggesting a link between HMGB1 deficiency in local tissue and circulating HMGB1 accumulation [48]. Next, we demonstrated that the source of



**Figure 1:** HMGB1 plays a dual role in acute pancreatitis. Increased stressors cause translocation of HMGB1 from the nucleus to the cytosol and then its release into the extracellular space in pancreatitis. Loss of intracellular HMGB1 in the pancreas leads to nuclear catastrophe and inflammatory nucleosome release, which can further promote inflammatory cell recruitment/activation and HMGB1 release. Finally, increased serum HMGB1 and nucleosomes cause systemic inflammatory response syndrome and multiple organ failure.

circulating HMGB1 in CH mice was from histone- and DNA-mediated recruitment and activation of macrophages [48]. *In vitro*, DNA inhibitor (Dnase I) and histone 3 (H3)-neutralizing antibodies significantly inhibited macrophage migration and HMGB1 release [48]. *In vivo*, anti-H3 neutralizing antibodies effectively reduced serum HMGB1 levels and reversed the phenotype of CH mice in acute pancreatitis. In addition to blocking histone activity by neutralizing antibodies, inhibition of histone release by antioxidant (e.g., N-acetyl-L-cysteine) also protected CH mice from acute pancreatitis. Finally, we determined whether blocking HMGB1 activity would change the phenotype of CH mice in response to suffering from pancreatitis. Indeed, we demonstrated that anti-HMGB1 neutralizing antibodies prolonged animal survival and decreased serum levels of tissue enzymes (e.g., amylase, lactate dehydrogenase, and myeloperoxidase) and pro-inflammatory cytokines (e.g., tumor necrosis factor- $\alpha$  and interleukin-6) in CH mice following pancreatitis [48]. These findings suggest that the crosstalk between intracellular and extracellular nuclear DAMPs (e.g., HMGB1 and histones) leads to the development of pancreatitis (Figure 1).

## Conclusion

HMGB1 is both an architectural nuclear protein and a DAMP. Despite the recent significant advances in understanding the opposing effects of intracellular and extracellular HMGB1 in acute pancreatitis, many questions remain. For example, what regulates the balance between levels of intracellular and extracellular HMGB1? One suggestion is the metabolism production from mitochondrial stress-driven HMGB1 translocation and release [51,52]. Another issue concerns the activity of HMGB1 from different types of death, as HMGB1 redox status may distinguish immunogenic and tolerogenic cell death [53]. Reagents that block HMGB1's release and activity ameliorate the symptoms in experimental pancreatitis; therefore, they will probably be tested in clinical trials. Additional large randomized studies are necessary to determine the utility of HMGB1 inhibitor in patients.

## Acknowledgment

We thank Christine Heiner (Department of Surgery, University of Pittsburgh) for her critical reading of the manuscript. This work was supported by the National Institutes of Health (NIH) (R01 CA160417 to D.T. and R01CA181450 to H.J.Z./M.T.L) and a 2013 Pancreatic Cancer Action Network-AACR Career Development Award (Grant Number 13-20-25-TANG). The work supporting the findings reviewed in this manuscript was aided by core support from the University of Pittsburgh Cancer Institute (NIH grant P30CA047904).

## References

- Whitcomb DC. Clinical practice. Acute pancreatitis. *N Engl J Med*. 2006; 354: 2142-2150.
- Shah AU, Sarwar A, Orabi AI, Gautam S, Grant WM, Park AJ, et al. Protease activation during *in vivo* pancreatitis is dependent on calcineurin activation. *Am J Physiol Gastrointest Liver Physiol*. 2009; 297: G967-973.
- Satoh A, Shimosegawa T, Kimura K, Moriizumi S, Masamune A, Koizumi M, et al. Nitric oxide is overproduced by peritoneal macrophages in rat taurocholate pancreatitis: the mechanism of inducible nitric oxide synthase expression. *Pancreas*. 1998; 17: 402-411.
- Sugita H, Yamaguchi Y, Ikei S, Yamada S, Ogawa M. Enhanced expression of cytokine-induced neutrophil chemoattractant (CINC) by bronchoalveolar macrophages in cerulean-induced pancreatitis rats. *Dig Dis Sci*. 1997; 42: 154-160.
- Gea-Sorlí S, Closa D. Role of macrophages in the progression of acute pancreatitis. *World J Gastrointest Pharmacol Ther*. 2010; 1: 107-111.
- Shrivastava P, Bhatia M. Essential role of monocytes and macrophages in the progression of acute pancreatitis. *World J Gastroenterol*. 2010; 16: 3995-4002.
- Hegyi P, Pandol S, Venglovecz V, Rakonczay Z Jr. The acinar-ductal tango in the pathogenesis of acute pancreatitis. *Gut*. 2011; 60: 544-552.
- Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. *Immunol Rev*. 2012; 249: 158-175.
- Kono H, Rock KL. How dying cells alert the immune system to danger. *Nat Rev Immunol*. 2008; 8: 279-289.
- Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. *J Leukoc Biol*. 2007; 81: 1-5.
- Kang R, Lotze MT, Zeh HJ, Billiar TR, Tang D. Cell Death and DAMPs in Acute Pancreatitis. *Mol Med*. 2014;.
- Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, et al. HMGB1 in health and disease. *Mol Aspects Med*. 2014.
- Bonaldi T, Langst G, Strohner R, Becker PB, Bianchi ME. The DNA chaperone HMGB1 facilitates ACF/CHRAC-dependent nucleosome sliding. *EMBO J*. 2002; 21: 6865-6873.
- Gerlitz G, Hock R, Ueda T, Bustin M. The dynamics of HMG protein-chromatin interactions in living cells. *Biochem Cell Biol*. 2009; 87: 127-137.
- Lange SS, Mitchell DL, Vasquez KM. High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage. *Proc Natl Acad Sci U S A*. 2008; 105: 10320-10325.
- Ohndorf UM, Rould MA, He Q, Pabo CO, Lippard SJ. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. *Nature*. 1999; 399: 708-712.
- Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, et al. Endogenous HMGB1 regulates autophagy. *J Cell Biol*. 2010; 190: 881-892.
- Livesey KM, Kang R, Vernon P, Buchser W, Loughran P, Watkins SC, et al. p53/HMGB1 complexes regulate autophagy and apoptosis. *Cancer Res*. 2012; 72: 1996-2005.
- Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, et al. HMGB1 promotes drug resistance in osteosarcoma. *Cancer Res*. 2012; 72: 230-238.
- Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. *Nature*. 2002; 418: 191-195.
- Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMGB-1 as a late mediator of endotoxin lethality in mice. *Science*. 1999; 285: 248-251.
- Hou W, Zhang Q, Yan Z, Chen R, Zeh HJ, Kang R, et al. Strange attractors: DAMPs and autophagy link tumor cell death and immunity. *Cell Death Dis*. 2013; 4: e966.
- Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. *Nat Rev Immunol*. 2005; 5: 331-342.
- Kang R, Tang D, Schapiro NE, Loux T, Livesey KM, Billiar TR, et al. The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. *Oncogene*. 2014; 33: 567-577.
- Xu J, Jiang Y, Wang J, Shi X, Liu Q, Liu Z, et al. Macrophage endocytosis of high-mobility group box 1 triggers pyroptosis. *Cell Death Differ*. 2014; 21: 1229-1239.
- Bianchi ME. HMGB1 loves company. *J Leukoc Biol*. 2009; 86: 573-576.
- Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. *Oncogene*. 2010; 29: 5299-5310.
- Yasuda T, Ueda T, Takeyama Y, Shinzeki M, Sawa H, Nakajima T, et al.

- Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. *Pancreas*. 2006; 33: 359-363.
29. Kocsis AK, Szabolcs A, Hofner P, Takacs T, Farkas G, Boda K, et al. Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis. *Pancreatology*. 2009; 9: 383-391.
  30. Lindstrom O, Tukiainen E, Kylanpaa L, Mentula P, Rouhiainen A, Puolakkainen P, et al. Circulating levels of a soluble form of receptor for advanced glycation end products and high-mobility group box chromosomal protein 1 in patients with acute pancreatitis. *Pancreas*. 2009; 38: e215-220.
  31. Yasuda T, Ueda T, Shinzeki M, Sawa H, Nakajima T, Takeyama Y, et al. Increase of high-mobility group box chromosomal protein 1 in blood and injured organs in experimental severe acute pancreatitis. *Pancreas*. 2007; 34: 487-488.
  32. Fortunato F, Burgers H, Bergmann F, Rieger P, Buchler MW, Kroemer G, et al. Impaired autolysosome formation correlates with Lamp-2 depletion: role of apoptosis, autophagy, and necrosis in pancreatitis. *Gastroenterology*. 2009; 137: 350-360.
  33. Gu H, Werner J, Bergmann F, Whitcomb DC, Buchler MW, Fortunato F. Necro-inflammatory response of pancreatic acinar cells in the pathogenesis of acute alcoholic pancreatitis. *Cell Death Dis*. 2013; 4: e816.
  34. Sawa H, Ueda T, Takeyama Y, Yasuda T, Shinzeki M, Nakajima T, et al. Blockade of high mobility group box-1 protein attenuates experimental severe acute pancreatitis. *World J Gastroenterol*. 2006; 12: 7666-7670.
  35. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. *Proc Natl Acad Sci U S A*. 2002; 99: 12351-12356.
  36. Yang ZY, Ling Y, Yin T, Tao J, Xiong JX, Wu HS, et al. Delayed ethyl pyruvate therapy attenuates experimental severe acute pancreatitis via reduced serum high mobility group box 1 levels in rats. *World J Gastroenterol*. 2008; 14: 4546-4550.
  37. Cheng BQ, Liu CT, Li WJ, Fan W, Zhong N, Zhang Y, et al. Ethyl pyruvate improves survival and ameliorates distant organ injury in rats with severe acute pancreatitis. *Pancreas*. 2007; 35: 256-261.
  38. Yang R, Shaufl AL, Killeen ME, Fink MP. Ethyl pyruvate ameliorates liver injury secondary to severe acute pancreatitis. *J Surg Res*. 2009; 153: 302-309.
  39. Luan ZG, Zhang H, Ma XC, Zhang C, Guo RX. Role of high-mobility group box 1 protein in the pathogenesis of intestinal barrier injury in rats with severe acute pancreatitis. *Pancreas*. 2010; 39: 216-223.
  40. Luan ZG, Ma XC, Zhang H, Zhang C, Guo RX. Protective effect of ethyl pyruvate on pancreas injury in rats with severe acute pancreatitis. *J Surg Res*. 2013; 181: 76-84.
  41. Hagiwara S, Iwasaka H, Uchida T, Hasegawa A, Asai N, Noguchi T. Danaparoid sodium prevents cerulein-induced acute pancreatitis in rats. *Shock*. 2009; 32: 94-99.
  42. Yuan H, Jin X, Sun J, Li F, Feng Q, Zhang C, et al. Protective effect of HMGB1 a box on organ injury of acute pancreatitis in mice. *Pancreas*. 2009; 38: 143-148.
  43. Zhang ZW, Zhang QY, Zhou MT, Liu NX, Chen TK, Zhu YF, et al. Antioxidant inhibits HMGB1 expression and reduces pancreas injury in rats with severe acute pancreatitis. *Dig Dis Sci*. 2010; 55: 2529-2536.
  44. Hagiwara S, Iwasaka H, Shingu C, Matsumoto S, Uchida T, Noguchi T. Antithrombin III prevents cerulein-induced acute pancreatitis in rats. *Pancreas*. 2009; 38: 746-751.
  45. Weng TI, Wu HY, Chen BL, Liu SH. Honokiol attenuates the severity of acute pancreatitis and associated lung injury via acceleration of acinar cell apoptosis. *Shock*. 2012; 37: 478-484.
  46. Yan S, Ding Y, Sun F, Lu Z, Xue L, Liu X, et al. Pretreatment of cisplatin in recipients attenuates post-transplantation pancreatitis in murine model. *Int J Biol Sci*. 2012; 8: 298-309.
  47. Jo IJ, Bae GS, Park KC, Choi SB, Jung WS, Jung SY, et al. *Scolopendra subspinipes mutilans* protected the cerulein-induced acute pancreatitis by inhibiting high-mobility group box protein-1. *World J Gastroenterol*. 2013; 19: 1551-1562.
  48. Kang R, Zhang Q, Hou W, Yan Z, Chen R, Bonaroti J, et al. Intracellular Hmgb1 inhibits inflammatory nucleosome release and limits acute pancreatitis in mice. *Gastroenterology*. 2014; 146: 1097-1107.
  49. Pandolfi SJ, Saluja AK, Imrie CW, Banks PA. Acute pancreatitis: bench to the bedside. *Gastroenterology*. 2007; 132: 1127-1151.
  50. Chen R, Kang R, Fan XG, Tang D. Release and activity of histone in diseases. *Cell Death Dis*. 2014; 5: e1370.
  51. Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1, oxidative stress, and disease. *Antioxid Redox Signal*. 2011; 14: 1315-1335.
  52. Yang L, Xie M, Yang M, Yu Y, Zhu S, Hou W, et al. PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. *Nat Commun*. 2014; 5: 4436.
  53. Tang D, Billiar TR, Lotze MT. A Janus tale of two active high mobility group box 1 (HMGB1) redox states. *Mol Med*. 2012; 18: 1360-1362.